Kalaris Therapeutics (NASDAQ:KLRS) reported quarterly losses of $(0.46) per share which beat the analyst consensus estimate of $(0.53) by 13.21 percent. This is a 81.75 percent increase over losses of $(2.52) per share from the same period last year.